Binding of Antigenic Peptide to the Endoplasmic Reticulum-resident Protein gp96/GRP94 Heat Shock Chaperone Occurs in Higher Order Complexes

ESSENTIAL ROLE OF SOME AROMATIC AMINO ACID RESIDUES IN THE PEPTIDE-BINDING SITE*

Nora A. LinderothDagger , Martha N. Simon§, James F. Hainfeld§, and Srin SastryDagger

From the Dagger  Laboratory of Molecular Genetics, The Rockefeller University, New York, New York 10021 and the § Department of Biology, Brookhaven National Laboratory, Upton, New York 11973

Received for publication, November 6, 2000, and in revised form, December 22, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Vaccination with heat shock protein gp96-antigenic peptide complexes produces a powerful specific immune response against cancers and infectious diseases in some experimental animal models, and gp96-peptide complexes are now being tested in human clinical trials. gp96 appears to serve as a natural adjuvant for chaperoning antigenic peptides into the immune surveillance pathways. A fundamental issue that needs to be addressed is the mechanism of binding of antigenic peptide to gp96. Here, we show using scanning transmission electron microscopy that recombinant gp96 binds peptide in stable multimeric complexes, which may have biological significance. To open the possibility for genetically engineering gp96 for improved immunogenicity and to understand if molecular recognition plays a role in the binding of antigenic peptide, we mutagenized some specific aromatic amino acids in the presumed peptide-binding pocket. Replacement of Tyr-667 or Tyr-678 to Ala reduced affinity for peptide whereas conversion of Trp-654 to Tyr increased peptide binding. Similarly, changing Trp-621 to Phe or Leu or Ala or Ile negatively affected peptide binding whereas changing Trp-621 to Tyr or Val positively affected peptide binding. Probing the peptide microenvironment in gp96-peptide complexes, suggested that hydrophobic interactions (and perhaps hydrogen bonding/stacking interactions) may play a role in peptide loading by gp96.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The endoplasmic reticulum (ER)1 is the organelle responsible for constant peptide trafficking. The most abundant peptide-binding protein in the lumen of ER is the heat shock chaperone gp96 (GRP94, Ref. 1). gp96 has drawn the attention of many investigators for its induction by glucose starvation, estrogen, and interferons and for its role in ischemia, tumor immunity, calcium, and peptide binding, as well as its role as a chaperone, a glycoprotein, and a phosphoprotein (reviewed in Ref. 2). gp96 and heat shock protein HSP90, its cytosolic paralog, share about 50% sequence homology (3). Both are dimeric proteins (4-6) and are also found as oligomers (7-10). Both HSP90 and gp96/GRP94 (1, 11) bind a variety of antigenic peptides in vivo and in vitro (for reviews, see Refs. 12-14). Intriguingly, gp96 acts as a chaperone of peptides and aids in provoking a strong immune response against peptide antigens (12). Its potential as a natural adjuvant for therapeutic cancer vaccines makes this protein highly significant for human health. The proposed role of gp96 is to ferry antigenic peptides into specialized antigen-presenting cells via receptor-mediated internalization of gp96-antigenic peptide complexes (15-17). The peptides are presumed to be transferred to and represented by MHC class I molecules (12, 18-22). Clearly, the primary event in the HSP-mediated immune response pathway appears to be the recognition and binding of antigenic peptides by gp96. In this context many questions remain unanswered; e.g. how are peptides selected, and what are the mechanisms of peptide binding by gp96? To address this, we developed a highly sensitive fluorescence-based assay for gp96/peptide binding (9) and mapped the minimal peptide-binding site to amino acid residues 624-630 in the C-terminal region of gp96 (23). A molecular model of the gp96 peptide-binding site was offered with the suggestion that the antigenic peptide may bind in a pocket. Here, to further explore the molecular interactions of peptide and gp96, we used STEM to show that gp96-peptide complexes exist in higher order multimeric complexes and used site-directed mutagenesis to understand the role of specific aromatic amino acid residues in the gp96 peptide-binding pocket.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Protein Expression and Purification-- Wild-type and mutant His-gp96 proteins were purified from plasmid-bearing Escherichia coli strain JM109 using published procedures (9, 10). Plasmid pHisGP96 encodes murine gp96 with an N-terminal His6 tag (10), and the mutants are described below. The purity and intactness of the proteins were assessed by electrophoresis in SDS-containing 10% polyacrylamide gels, silver staining, and immunoblotting (9).

Preparation of Nanogold-labeled Peptide-- Peptide RGYVYQGLKSGLRRASLGRS is a known ligand of gp96 that contains a vesicular stomatitis virus-derived core sequence (23). It was synthesized (Alpha Diagnostic, San Antonio, TX) and purified by HPLC. The peptide was covalently labeled with nanogold using the amine-reactive reagent sulfo-N-hydroxysuccinimido nanogold according to the manufacturer's protocol (Nanoprobes, Yaphank, NY). A 10-fold molar excess of peptide over nanogold was used to maximize the coupling efficiency. To purify nanogold-peptide from free peptide and nanogold, the reaction was subjected to ultrafiltration (10 kDa molecular mass cut-off) and washed repeatedly with 0.1 M triethylammonium acetate-water. The retentate was filtered (0.45 micron) and the nanogold-peptide conjugate was purified by C18 reverse phase HPLC. The following HPLC gradient was used: 10 min of 0.1 M TEAA-water and a linear ramp from 100% 0.1 M TEAA-water to 100% MeOH in 30 min. The nanogold-peptide-containing fractions were identified using inline absorption spectra (A280, A420) collected using a diode array detector (Hewlett-Packard 1090 series HPLC) and identified by polyacrylamide gel electrophoresis. Fractions containing nanogold-peptide were dried in vacuuo and dissolved in water. Portions were separated on SDS-containing 15% polyacrylamide gels, which were stained with LI silver enhancement solution (Nanoprobes) to detect gold-containing bands.

Visualization of Nanogold-Peptide-gp96 Complexes by STEM-- A binding mixture consisting of 5 µM gp96 and 5 µM nanogold-peptide in 10 mM Na+/HEPES, pH 7.8, 150 mM NaCl, 1 mM MgCl2 was incubated for several hours at room temperature. Assuming that the Kd for the modified peptide was equivalent to that of the unmodified peptide (10), greater than 90% of the nanogold-labeled peptide would have been bound to gp96. The STEM analysis was carried out as described previously (10, 24).

Construction of Mutants-- Mutations were introduced into the gene for gp96 by oligonucleotide-directed site-specific mutagenesis of pHisGP96 (10). Deoxyuracil-containing single-stranded pHisGP96 DNA was extracted from phagemids grown in an E. coli host with dut ung mutations (25). The mutagenic oligonucleotides used are listed in Table I. Sequenced DNA intervals containing the mutations were reselected and cloned into naïve pHisGP96 to ensure that no clones had spurious mutations.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Mutagenic oligonucleotides

Circular Dichroism-- WT and mutant His-gp96 proteins (1 mg/ml) were dialyzed versus 20 mM sodium phosphate buffer, pH 7.8, and the spectra were acquired and data processed as described before (10).

Fluorescence Assays-- Peptide-pyrene conjugate was prepared and purified by HPLC as described previously (9). Equilibrium peptide-pyrene binding to WT and mutant His-gp96 proteins was done in a final volume of 12 µl of binding buffer (20 mM HEPES/Na+, pH 7.8, 200 mM NaCl, 2 mM MgCl2). A fixed concentration of gp96 (typically 5 µM) was mixed with different concentrations of peptide-pyrene (400 pM to 5 µM). Binding mixtures were prepared at 25 °C and incubated at room temperature for ~3 h. Control reactions were prepared with matched concentrations of peptide-pyrene alone. Binding buffer was added to a final volume of 650 µl. The steady-state fluorescence intensity of the samples was measured and corrected for background buffer signal. All steady-state fluorescence spectra were acquired at 23 °C using JOBIN YVON/SPEX fluorolog3 tau  instrument (Instruments, S.A. Inc., NJ) as previously described (9). The excitation was performed at 340 nm and the emission was measured at either 376 or 396 nm with a 5-nm bandpass set for both monochromators.

Intensity-average lifetime (<tau >) measurements were acquired by using the phase-shift and demodulation method (9, 26). The standard-lifetime compounds were: p-Terphenyl (lifetime 1.0 ns) and 1,4-bis[5-phenyl-2-oxazolyl]benzene (lifetime 1.3 ns). A scattering agent, LudoxTM in water (0 ns lifetime), was used to correct for baseline fluctuations during lifetime acquisition. Lifetimes of the experimental samples were measured against 1,4-bis[5-phenyl-2-oxazolyl]benzene in MeOH. Excitation was performed at 340 nm and emission was measured by using the T-detector fitted with a neutral density filter (KV340, Schott) to cutoff stray light below 340 nm. The AC/DC signals were balanced for the reference and experimental samples. Twelve modulated excitation frequencies ranging from 1 to 10 MHz were synthesized. A minimum of 5 and a maximum of 10 repeat measurements of phase and demodulation were taken. Intensity-average lifetime was calculated from the fractional amplitude (alpha ) and lifetime (tau ) using both the phase-shift and demodulation data. Post-experiment iterative lifetime modeling program version 2.1 (SPEX) was used to fit the data to a multiexponential decay model, giving fits with good chi 2 values (Table II). Fitting the lifetime data to a single-exponential model gave unacceptable chi 2 values.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Lifetime parameters for gp96-peptide-pyrene complexes



    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Binding of Peptide to gp96 as seen by STEM-- Recently, we used STEM to show that gp96 forms higher order multimers larger than dimers (10). It was shown that native mouse protein also forms higher order structures (10). We wished to know if peptide could be bound to gp96 in these large multimeric structures. Therefore we prepared antigenic peptide conjugated to 1.4 nm-nanogold and used STEM to analyze the peptide-gp96 complexes. STEM is particularly useful for studying higher order structures because one observes bare, unstained molecules and can obtain estimates of masses and dimensions. For this purpose STEM is superior to solution-based techniques and other types of electron microscopy. Moreover, using STEM one can directly visualize and count nanogold-peptide particles (28, 29). Nanogold-peptide-gp96 complexes were prepared at concentrations approaching intracellular gp96 concentrations (~5-10 µM, Ref. 1) and the complexes were diluted just prior to visualization by STEM (Fig. 1). Nanogold-peptide was seen as bright white spots against the background of gray gp96 multimeric structures resting on a black surface (Fig. 1, A-E). It was not possible to determine whether a given nanogold-peptide resided on a distal or proximal surface of a complex because with STEM one sees a two-dimensional (transmission) projection of the particle. Isolated nanogold-peptide was also seen in some fields (Fig. 1, F-J) but at a much lower density than observed with or in close proximity to gp96 (Fig. 1, A--E). In general, these examples of STEM images showing massive gp96 multimers are similar to ones seen earlier that were prepared without peptide (10) except that we did not observe many smaller complexes of gp96 such as monomer/dimer, tetramers etc. This suggested that gp96-peptide complexes were assembled in large multimers and that dilution and washing did not dissociate bound peptide, consistent with our previous findings (10). We manually counted the number of nanogold-peptide associated with gp96 complexes and found that the number of bound nanogold-peptide roughly corresponded to the number of gp96 monomer units in a complex (Fig. 1, below). With some types of samples, e.g. large viruses, nanogold-signal from a distal surface might be obscured because of sample thickness. However, this is unlikely to be the case with gp96 complexes. It is possible that some gp96 molecules in the multimeric complex failed to bind nanogold-peptide or lost their nanogold-peptide during sample processing. The dimensions of the multimeric complexes suggested no specific geometric configuration, only unordered shapes (Fig. 1, A-E and lower table), consistent with previous findings (10). Statistical analysis was not possible with this limited amount of data. Many of the molecules (not shown) appeared to be "denatured" because of unknown reasons.



View larger version (72K):
[in this window]
[in a new window]
 
Fig. 1.   STEM analysis of higher order complexes of the nanogold-peptide-gp96 complex. Panels A-E show images of gp96 multimeric complexes with bound nanogold-peptide, whereas panels F-J show isolated free nanogold-peptide. The table below gives a semiquantitative analysis of the complexes. Total masses were computed using a PC mass program as described before (10). Visible nanogold particles were counted manually from onscreen images. A collective mass for nanogold-peptide (Au-pep) was estimated using a value of 20 kDa each. This value was subtracted from the total mass of the nanogold-peptide-gp96 complex, and the remainder was divided by the molecular mass of gp96 monomer (94.010 kDa) to estimate the number of gp96. The dimensions of the complexes were estimated by counting the number of pixels in enlarged views of images and were corrected for the appropriate magnification factor used to obtain the different images.

The finding that gp96-peptide complexes are assembled in massive multimers is potentially important because such a binding mode may facilitate the transport and receptor-mediated uptake of gp96-peptide complexes into antigen-presenting cells (15). These large complexes may sequester peptide more effectively than smaller ones (dimers, tetramers, etc.), resulting in more efficient delivery of antigenic peptides to their subcellular destination in the antigen presenting cell for further processing. Also, higher order complexes may be more easily bound by the cognate gp96 receptors, because the high local concentration of gp96-peptide complexes could greatly enhance the frequency of collisional interaction with gp96 receptors. Thus we suggest a biological significance for the higher order assembly of gp96-peptide complexes.

Rationale for Site-specific Mutagenesis-- We recently identified the peptide-binding site of gp96 based on photochemical cross-linking studies (23). Because no high resolution structure exists for the gp96- or HSP90-peptide complex, we constructed a computer model depicting the peptide-binding pocket of gp96 (for details and rationalization see Ref. 23). This model has served as a guide for further exploration of the molecular nature of gp96-peptide interactions. Crystallographic and NMR studies of other peptide-binding proteins have revealed that aromatic amino acids such as Tyr and Trp play an important, although nonexclusive role in optimal peptide-protein interactions (reviewed in Ref. 30). For example, in the MHC I molecule-antigenic peptide complex, tyrosyl residues from the MHC form H-bonds with "anchor" tyrosyl residues in the bound peptide (31). Also, most of the specificity in the MHC class II molecule HLA·DR1-peptide complex comes from binding to an N-terminal tyrosine in peptide. Likewise, the SH2 domains of Src-tyrosine kinase and Syp-tyrosine phosphatase utilize phosphotyrosines in peptide for their interactions (32, 33).

To better understand the microenvironment of the peptide-binding pocket of gp96, we turned to site-specific mutagenesis. The peptide-binding domain of gp96 contains five Tyr and three Trp residues. Site-specific mutagenesis was used to alter these codons in expression vector pHisGP96 (Table I). Each of the Tyr codons was individually changed to an Ala codon; a mutant with both Y677A and Y678A was also constructed. Alanine was selected as the replacement amino acid for Tyr because it lacks the large bulky hydrophobic side chain proposed to interface with peptide ligand but retains some hydrophobicity. Alanine is the most common amino acid in proteins, does not introduce new hydrogen bonding or charge and is found in both buried and exposed regions of proteins and in all types of secondary structure (27). In the case of Trp-codon alterations, Trp-485 was replaced with Tyr because nearly all HSP90 proteins have Tyr at the equivalent position. Trp-621 was substituted with Ala, Ile, Leu, and Val, because all of these residues can be found at this position in various HSP90 homologs. Mutants with Phe-621 and Tyr-621 were also tested, in case gp96 structure or function might require a large hydrophobic side-chain at this position. In place of Trp-654, only conservative replacements to Phe, Leu, and Tyr were made; Trp is the only amino acid found in gp96 homologs at this position.

Characterization of Mutant gp96 Proteins-- gp96 mutant proteins, which had N-terminal His6 tags, were purified using Ni2+-affinity chromatography and analyzed by SDS-gel electrophoresis and Western blotting (Fig. 2). Silver staining of the gel showed that the mutant proteins migrated as single bands similar to the WT gp96 protein (Fig. 2A). Western blotting with a C terminus-recognizing anti-KDEL antibody indicated that the proteins were full-length and intact (Fig. 2B and not shown). The results indicated that the mutant protein preparation was >95% pure gp96.



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   SDS-polyacrylamide gel (10%) of purified WT and mutant gp96 proteins after silver-staining (panel A), and immunoblot of purified WT and selected mutant proteins with an anti-KDEL (C-terminal) antibody (panel B). The two mutant proteins not shown here (W654F, Y677A+Y678A) gave results identical to these.

To find out if single mutations in the gp96 protein affected secondary structure, we used CD spectroscopy. CD is a sensitive method for measuring changes in protein conformation. An example of the CD data is shown in Fig. 3, top panel. Data for the other mutants are not shown because they were similar to Fig. 3 (top panel) within experimental error. The CD data showed that global secondary structure content was not appreciably affected by the changes in single amino acids. However, we cannot exclude the possibility that local conformation of small segments in the protein may have been affected by the point mutations, which may affect peptide binding.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   CD spectra of WT and selected mutant gp96 proteins (top panel) and selected emission spectra of WT and mutant protein-peptide-pyrene complexes (bottom panel). The CD values were normalized as described before (10). All other mutant proteins not shown here showed similar results with these techniques.

Peptide Binding by WT and Mutant Proteins-- To assay for peptide binding in solution and to quantitate the differences in peptide loading efficiencies of gp96 mutant proteins, we used a pyrene-labeled peptide ligand. The detailed procedure for synthesis of this fluorescent peptide and method of assay for peptide binding by gp96 have been described elsewhere (9, 10). Briefly, the fluorescent group pyrene was attached to the unique lysine residue in the peptide (SLSDLRGYVYQGLKSGNVS) via an amide linkage. Here the pyrene serves as an optical sensor of the changes in the environment of the peptide-binding site. When peptide-pyrene binds to gp96 there is an increase in the excited-state lifetime of pyrene because it is in a hydrophobic environment (10). By measuring the fluorescence intensity and the intensity-averaged lifetime of pyrene, we can gauge peptide binding affinities as well as the extent of changes in hydrophobicity as previously demonstrated (9, 10). This assay has several advantages over STEM for the present purpose. 1) The fluorescence assay allows for "sensing" the microscopic changes in pyrene environment (which may translate into peptide environment) brought about by alterations in amino acid side chains. 2) The fluorescence assay is quantitative; therefore potentially a hierarchical gradation of effects of the mutations is possible; and 3) it is much more rapid than STEM and is solution-based.

Fig. 3 (bottom panel) shows examples of pyrene emission spectra of peptide-pyrene-gp96 complexes. Spectra for other mutant gp96-peptide complexes are not shown because the basic changes were similar to those in Fig. 3. In all cases, binding of peptide-pyrene resulted in an increase in the intensity of emission bands at 378 and 396 nm compared with the free peptide-pyrene (Fig. 3, green line). To help describe the molecular interactions that the pyrene fluorophore experiences and to understand the local environment of the fluorophore we measured, in parallel to the emission spectra, the lifetime parameters (Table II). The intensity-average lifetime (<tau >) of pyrene increased when WT gp96 bound to peptide, indicating that the pyrene moiety had moved into a hydrophobic environment in the peptide-binding site in gp96-peptide complexes (Table II). The increase in <tau > is because of sequestration of pyrene from dynamic solute quenching of the excited state. Binding of peptide-pyrene to mutant gp96 proteins either increased or decreased the steady-state intensity and lifetime of pyrene compared with the WT gp96-peptide complex. Changes in steady-state intensities were quantitatively expressed by constructing binding isotherms, which reflected gross affinity of peptide to gp96 (Fig. 4). Here the steady-state fluorescence intensity at 378 nm was plotted against peptide-pyrene concentration. Intensity-averaged lifetime was used as a measure of changes in the peptide microenvironment (hydrophobicity) and affinity (see below for more discussion).2



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Binding of peptide-pyrene to WT and mutant gp96 proteins with changes in Tyr and Trp residues. The curves were constructed from data sets (n = 3) obtained by titrating a fixed concentration of gp96 with increasing concentrations of peptide-pyrene (400 pM to 5 µM) as described under "Experimental Procedures." In a given panel, the fluorescence from mutant-peptide complexes is plotted relative to the fluorescence value of WT complexes using the same scale.

Mutation of Tyr-667 or Tyr-678 to Ala caused a marked decrease in steady-state fluorescence and intensity-average lifetime (Fig. 4 top panel and Table II, <tau >) compared with the WT. However, Y575A, which has an altered residue that was predicted to be farther away from the peptide (23) showed a lesser reduction in peptide binding (Fig. 4, top panel) and a corresponding lack of significant effect on the microenvironment, as indicated by the intensity-average lifetime parameter (Table II, <tau >). Similarly, mutant proteins Y652A and Y677A did not show appreciable changes in the intensity-average lifetime (Table II, <tau >). It is interesting to note that whereas Y678A affected both peptide binding and the pyrene environment, Y677A affected neither. Furthermore, with the double mutant protein, Y677A + Y678A, the intensity-average lifetime decreased to a similar extent as seen for the single mutant protein Y678A (Table II). This clearly shows that the two neighboring tyrosines (Tyr-677 and Tyr-678) are nonequivalent and that Tyr-678 is perhaps closer to pyrene and may interact with peptide. These findings highlight the crucial role that tyrosines may play in the peptide-binding site and demonstrate that the environment of the bound peptide can be affected in such a way as to decrease peptide binding. Tyrosines closest to the peptide (at least based on our model Ref. 23) did indeed affect the peptide environment. In the MHC class I molecule-peptide complex, tyrosyl residues serve as anchors to restrict size-selectivity of antigenic peptide (31). Whereas any parallel between MHC class I molecules and gp96 is debatable, it is intriguing to note that tyrosines serve an essential role in peptide loading by gp96. The Tyr may be involved in stacking/hydrophobic interactions with peptide as observed in other types of protein-peptide interactions (30).

Next, we examined the potential role of another set of aromatic amino acids: the tryptophanyl residues. Earlier, we speculated based on resonance energy transfer between tryptophan and pyrene in peptide-pyrene-gp96 complexes that one or more Trp residues were close to the bound peptide (9). To examine the role of Trp residues in peptide loading, we focused on the three tryptophanyl residues (Trp-485, Trp-621, and Trp-654) closest to the peptide in the presumed peptide-binding pocket (23). Trp-654 is a highly conserved residue in gp96 paralogs, and HSP90 family of proteins and Trp-621 is closest to the minimal contact region (residues 624-630) that was identified by cross-linking peptide to gp96 (23). Mutation of Trp654 to Phe or Leu did not significantly alter gross peptide binding nor did these mutations affect the microenvironment as indicated by the relatively little change in the intensity-average lifetimes (Fig. 4, bottom panel; Table II, <tau >). The same was true for W485Y, which presumably lies farther away from the peptide-binding site (23). W654Y mutant gp96 appeared to bind peptide better than WT (Fig. 4, bottom panel) and the peptide-binding environment appeared to be affected as well, i.e. increased hydrophobicity because the <tau > increased (Table II). These data suggest for the first time that mutagenesis can be used to engineer gp96 for greater peptide binding affinity. Furthermore, addition of a hydroxyl group (in W654Y, note that W654F has no affect) may facilitate new interaction such as H-bonding, which may have increased peptide affinity. The finding that the W654Y mutant protein (and others, see below) binds peptide better than WT gp96 opens the door to envisioning an improved gp96-peptide vaccine if one assumes that peptide affinity is correlated to immunogenicity, an assumption that needs further investigation.

Because Trp-621 was predicted to be closest to the bound peptide (23) we wanted to examine in greater detail the effects of mutation at this position (Fig. 5). Mutation of Trp-621 to either Ala, Phe, Ile, or Leu caused a reduction in peptide binding compared with WT gp96 (Fig. 5, top panel). The intensity-average lifetime decreased somewhat, suggesting that these mutations moderately affect binding pocket environment (Table II, <tau >). Interestingly, change to either W621Y or W621V significantly increased peptide binding relative to WT protein (Fig. 5, bottom panel). Concomitantly, the peptide-binding environment of the pocket also changed to greater hydrophobicity because the intensity-average lifetime of pyrene increased significantly (Table II, <tau >). The fact that substitution of Trp-621 with Ile or Leu negatively affected peptide binding whereas substitution of Val affected peptide binding positively suggested that both hydrophobicity (which is similar for Ile, Leu, and Val) and the length of the side chain influenced peptide binding. Because substitution with Ala had a negative effect, the extra "greasy" methyls were important. The substitution of Trp-621 with Tyr affected peptide binding positively (Fig. 5, bottom; Table II). Putting all these results together, we suggest roles for hydrophobic interactions and hydrogen bonding (because W621F negatively affected peptide binding) in peptide binding to gp96.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Binding of peptide-pyrene to Trp-621 mutant gp96 proteins. The curves were constructed from data sets (n = 3) obtained by titrating a fixed concentration of gp96 with increasing concentrations of peptide-pyrene (400 pM to 2.2 µM) as described under "Experimental Procedures." The fluorescence from mutant-peptide complexes is plotted relative to the fluorescence value of WT complexes using the same scale.

The studies described here attempt to decipher the molecular nature of the interaction of antigenic peptide with gp96 by using site-specific mutagenesis of gp96. It is important to note that because a high resolution crystal structure is unavailable, a model-based approach was used for design of experiments. The finding that gp96 binds peptide in very large molecular complexes, as shown here (Fig. 1), could explain some of the difficulties in obtaining crystallographic models. The peptide-gp96 complexes appear to be organized in no specific geometric lattices, perhaps adding to the difficulty.

Steady-state fluorescence intensity and intensity-averaged lifetime of the pyrene probe are used to measure peptide affinity and changes in local environment of the peptide. It is likely that the affinity of peptide is altered by changes in the internal milieu (hydrophobicity) of the binding pocket. Indeed, these two properties viz. peptide affinity and hydrophobicity of the binding pocket, may be related and are simply two sides of the same coin. To get a better perspective, data from titration experiments were used to make our conclusions regarding the difference in gross peptide affinity. Differences in intensity-averaged lifetime may reflect changes in both affinity and hydrophobicity because the fluorescence quantum yield is related to the excited-state lifetime (26).

Our work suggests that hydrophobic interaction and hydrogen bonding and/or stacking interactions could play an essential role in peptide stability in the binding pocket. Some substitutions in the presumed peptide binding pocket that introduce Tyr residues (W654Y and W621Y) appear to positively influence peptide binding whereas changes to other residues such as Trp-621 to Phe, Leu, Ala, or Ile had a negative effect. This may suggest an important role for Tyr in peptide binding by gp96 (as seen with other peptide-binding proteins Ref. 31)). The observation that some specific substitutions positively or negatively modulate peptide binding could potentially be a useful way to engineer new mutant gp96 proteins and to investigate their immunogenic potencies. Such a study might help provide insights into the long standing and unresolved issue of whether peptide binding can be correlated to immunogenicity of gp96-peptide complexes. Furthermore, this work points to the possibility that there may be peptide selectivity by gp96 based on molecular recognition because specific alterations in key amino acids in gp96 do appear to affect peptide affinity for better or for worse. The fact that there are gp96 mutant proteins that appear to bind peptide better than WT suggests that the WT gp96 peptide-binding pocket may have evolved in a way that balanced peptide binding with the potential need to exchange/transfer bound peptide to other molecules such as co-chaperones and MHC.


    ACKNOWLEDGEMENTS

We thank Dr. Michael Goger (spectroscopy facility at Rockefeller University) for making available the CD spectrometer. We are grateful to Dr. Joseph S. Wall (Brookhaven National Laboratory, BNL) for the PC mass program for STEM image analysis. The BNL STEM is an NIH Supported Resource Center with additional support provided by United States Department of Energy, Office of Biological and Environmental Research.


    FOOTNOTES

* This work was supported in part by grants from the Cancer Research Inst., NY, Antigenics L.L.C, NY, Hewlett Packard Foundation (to S. S.), and Grant P41-RR01777 from the National Institutes of Health and the United States Department of Energy Office of Biological and Environmental Research (to M. N. S. and J. F. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Laboratory of Molecular Genetics, Box 174, The Rockefeller University, 1230 York Ave., New York, NY 10021. E-mail: sastrys@rockvax.rockefeller.edu.

Published, JBC Papers in Press, January 8, 2001, DOI 10.1074/jbc.M010059200

2 Significant differences in <tau >, generally an increase or decrease of >= 40 ns, compared with that in the WT complex were used for making conclusions.


    ABBREVIATIONS

The abbreviations used are: ER, endoplasmic reticulum; MHC, major histocompatibility antigen; HPLC, high performance liquid chromatography; WT, wild-type.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES


1. Koch, G., Smith, M., Macer, D., Webster, P., and Mortata, R. (1986) J. Cell Sci. 86, 217-232[Abstract]
2. Csermely, P., Schnaider, T., Soti, C., Prohaszha, Z., and Nardai, G. (1998) Pharmacol. Ther. 79, 129-168[CrossRef][Medline] [Order article via Infotrieve]
3. Gupta, R. S. (1995) Mol. Biol. Evol. 12, 1063-1073[Abstract]
4. Minami, Y., Kimura, Y., Kawasaki, H., Susuki, K., and Yahara, I. (1994) Mol. Cell. Biol. 14, 1459-1464[Abstract]
5. Welch, W. J., and Feramisco, J. R. (1982) J. Biol. Chem. 257, 14949-14959[Abstract/Free Full Text]
6. Wearsch, P. A., and Nicchitta, C. V. (1996) Biochemistry 35, 16760-16769[CrossRef][Medline] [Order article via Infotrieve]
7. Minami, Y., Kawasaki, H., Miyata, Y., Susuki, K., and Yahara, I. (1991) J. Biol. Chem. 266, 10099-10103[Abstract/Free Full Text]
8. Wearsch, P. A., Voglino, L., and Nicchitta, C. V. (1998) Biochemistry 37, 5709-5719[CrossRef][Medline] [Order article via Infotrieve]
9. Sastry, S., and Linderoth, N. (1999) J. Biol. Chem. 274, 12023-12035[Abstract/Free Full Text]
10. Linderoth, N. A., Simon, M. N., Rodionovaz, N. A., Cadene, M., Laws, W. R., Chait, B. T., and Sastry, S. (2001) Biochemistry 40, 1483-1495[CrossRef][Medline] [Order article via Infotrieve]
11. Minami, Y., Kawasaki, H., Susuki, K., and Yahara, I. (1993) J. Biol. Chem. 268, 9604-9610[Abstract/Free Full Text]
12. Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L. (1998) Immunity 8, 657-665[Medline] [Order article via Infotrieve]
13. Soti, C., and Csermely, P. (1998) Path. Oncol. Res. 4, 316-321[Medline] [Order article via Infotrieve]
14. Nicchitta, C. V. (1998) Curr. Opin. Immunol. 10, 103-109[CrossRef][Medline] [Order article via Infotrieve]
15. Binder, R. J., Han, D. K., and Srivastava, P. K. (2000) Nat. Immunol. 1, 151-155[CrossRef][Medline] [Order article via Infotrieve]
16. Arnold-Schild, D. D., Hanau, D., Spehner, D., Schmid, C., Rammensee, H.-G., de la Salle, H., and Schild, H. (1999) J. Immunol. 162, 3757-3760[Abstract/Free Full Text]
17. Wassenberg, J. J., Dezfullian, C., and Nicchitta, C. V. (1999) J. Cell Sci. 112, 2167-2175[Abstract/Free Full Text]
18. Suto, R., and Srivastava, P. K. (1995) Science 269, 1585-1588[Medline] [Order article via Infotrieve]
19. Blachere, N. E., Li, Z., Chandawarkar, R. Y., Suto, R., Jaikaria, N. S., Basu, S., Udono, H., and Srivastava, P. K. (1997) J. Exp. Med. 186, 1315-1322[Abstract/Free Full Text]
20. Ishii, T., Udono, H., Yamano, T., Ohta, H., Uenaka, A., Ono, T., Hizuta, A., Tanaka, N., Srivastava, P. K., and Nakayama, E. (1999) J. Immunol. 162, 1303-1309[Abstract/Free Full Text]
21. Srivastava, P. K., Udono, H., Blachere, N. E., and Li, Z. (1994) Immunogenetics 39, 93-98[Medline] [Order article via Infotrieve]
22. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. (1997) Science 278, 117-120[Abstract/Free Full Text]
23. Linderoth, N. A., Popowicz, A., and Sastry, S. S. (2000) J. Biol. Chem. 275, 5472-5477[Abstract/Free Full Text]
24. Wall, J. S., Hainfeld, J. F., and Simon, M. N. (1998) Methods Cell Biol. 53, 139-166[Medline] [Order article via Infotrieve]
25. Kunkel, T. A., Bebenek, K., and McClary, J. (1991) Methods Enzymol. 204, 125-139[Medline] [Order article via Infotrieve]
26. Lakowicz, J. R. (1983) Principles of Fluorescence Spectroscopy , Vol. 10 , pp. 128-130, Plenum Press, NY
27. Wachsman, J. T., and Drake, J. W. (1987) Genetics 115, 405-417[Abstract/Free Full Text]
28. Gregori, L., Hainfeld, J. F., Simon, M. N., and Goldgaber, D. (1997) J. Biol. Chem. 272, 58-62[Abstract/Free Full Text]
29. Wall, J. S., and Hainfeld, J. F. (1986) Annu. Rev. Biophys. Biophys. Chem. 15, 355-376[CrossRef][Medline] [Order article via Infotrieve]
30. Stanfield, R. L., and Wilson, I. A. (1995) Curr. Opin. Struct. Biol. 5, 103-113[CrossRef][Medline] [Order article via Infotrieve]
31. Zhang, W., Young, A. C. M., Imarai, M., Nathenson, S. G., and Sacchettini, J. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8403-8407[Abstract]
32. Waksman, G., Shoelson, S. E., Pant, N., Cowburn, D., and Kuriyan, J. (1993) Cell 72, 779-790[Medline] [Order article via Infotrieve]
33. Lee, C. H., Kominos, D., Jaques, S., Margolis, B., Schlessiger, J., Shoelson, S. E., and Kuriyan, J. (1994) Structure 2, 423-438[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.